Full-Time

Quality Assurance Manager

Sotera Health

Sotera Health

1,001-5,000 employees

Outsourced sterilization and lab testing provider.

No salary listed

Marion, OH, USA

In Person

Bachelor's

Category
QA & Testing (1)
Required Skills
Quality Assurance (QA)
Data Analysis

Get referred to Sotera Health

See people who can refer or advise you

Requirements
  • A minimum Bachelor of Arts or Bachelor of Science degree in a related field is required.
  • Three to five years of quality assurance experience in the medical services or medical products area is required, or extensive quality science training with a proven understanding of people's motivation and proven leadership potential.
  • Excellent written and verbal communication skills are required.
  • Above-average computer skills are required.
  • The employee must be medically approved for respirator use in the EO facility.
  • The employee must tolerate exposure to 120 degrees Fahrenheit and 60% relative humidity for 20 minutes in the EO facility.
  • The employee must complete all required training for a Quality Assurance Manager outlined in the training manual.
Responsibilities
  • Maintain compliance with applicable regulatory requirements, including the Food and Drug Administration, Occupational Safety and Health Administration, Environmental Protection Agency, United States Department of Agriculture, and Nuclear Regulatory Commission.
  • Pursue continuous process and quality improvement using internal indices and external audits and reports.
  • Coordinate the determination and reporting of non-conformance causes, implement corrective actions and process improvements, and assist with retraining.
  • Initiate or oversee the change-control process.
  • Analyze facility data to identify trends and initiate required actions.
  • Coordinate activities for Food and Drug Administration, International Organization for Standardization, customer, internal, and other regulatory audits.
  • Conduct internal compliance audits and maintain appropriate records.
  • Maintain facility quality records and procedures.
  • Coordinate and maintain personnel dosimetry records.
  • Coordinate system requalification activities with plant Operations.
  • Assist Corporate Quality Assurance with special projects and assignments.
  • Coordinate facility management reviews.
  • Coordinate and maintain facility risk analysis.
  • Coordinate environmental monitoring and maintain personnel badge-testing records.
  • Execute equivalency and retrospective revalidation studies and reports where applicable.
  • Coordinate or execute process validations and calibrations where required.
  • Review and release batch records for processed materials.
  • Assist in establishing departmental objectives that support facility goals.
  • Communicate the company quality policy and values and motivate employees regarding the critical nature of the service.
  • Participate in hiring, retention, motivation, and development of qualified Quality Assurance and Validations personnel, if applicable.
  • Assist with new-employee orientation and job-function, good manufacturing practice, safety, and developmental training as required.
  • Interact with all functions within the plant.
  • Provide subordinates with clear and measurable objectives.
  • Maintain all quality-related training programs.
  • Perform other tasks assigned by the supervisor.
Desired Qualifications
  • Comparable experience in the food industry is desirable in lieu of medical experience for food irradiation facilities.
  • Extensive quality science training, such as American Society for Quality training, may substitute for the specified medical-services or medical-products experience.

Sotera Health provides sterilization and lab testing services to ensure the safety of medical devices, pharmaceuticals, and food products. The company operates through three divisions: Sterigenics, which uses methods like Gamma and X-ray to eliminate contaminants; Nordion, which supplies the Cobalt-60 isotopes needed for irradiation; and Nelson Labs, which performs over 800 microbiological and analytical tests. Unlike many competitors, it offers a fully integrated supply chain by producing its own sterilization sources while maintaining a global network of 63 facilities and labs. Its goal is to protect global health by providing the mission-critical services required to bring safe healthcare products to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Broadview Heights, Ohio

Founded

2017

Get referred to Sotera Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 9.2% to $321 million; management raised full-year guidance.
  • Alton Shader became CEO on May 26, 2026, while leverage fell to three times.
  • Nordion’s January 2026 domestic Cobalt-60 initiative and 2026 capacity builds extend growth runway.

What critics are saying

  • Georgia EO trials continue, and California trials are now scheduled for January or April 2027.
  • EPA EO compliance already drives $51 million of 2026 environmental capex, pressuring free cash flow.
  • A severe adverse verdict or injunction at Sterigenics could cripple revenue and trigger existential restructuring.

What makes Sotera Health unique

  • Sterigenics, Nordion, and Nelson Labs create bundled, regulated healthcare infrastructure customers rarely replace.
  • Nordion’s January 2026 U.S. Cobalt-60 partnership with Westinghouse and PSEG deepens supply moat.
  • Sotera’s 48 facilities across 13 countries embed switching costs in validation-heavy sterilization workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Education Assistance

Employee Assistance Program (EAP)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 19th, 2026
Sotera Health beats Q2 revenue estimates by 3.8%, posts 9.2% year-on-year growth

Sotera Health Company reported Q2 revenues of $321.4 million, up 9.2% year on year and exceeding analyst expectations by 3.8%. The company, which provides sterilisation services, lab testing, and advisory services for medical devices, pharmaceuticals, and food products, delivered strong results with impressive beats on organic revenue and earnings per share estimates. Chief executive officer Alton Shader noted the company achieved high-single-digit growth through focused execution across all three business units. The stock rose 2.9% following the earnings announcement. Within the research tools and consumables sector, the nine tracked stocks collectively beat revenue consensus estimates by 1.7% in Q2. Share prices across the sector gained an average of 2% following the results. Next quarter's revenue guidance was in line with expectations.

Yahoo Finance
Aug 10th, 2026
McIntyre Partnerships sees Sotera Health doubling after litigation wins and PE overhang clears

McIntyre Partnerships, a US investment firm, highlighted Sotera Health Company in its Q2 2026 investor letter. The healthcare sterilisation company reported positive first-quarter results, with its Sterigenics segment returning to high single-digit organic growth following COVID-related destocking in 2023 and 2024. Sotera Health achieved a significant legal victory in its Georgia litigation, with a judge dismissing five lawsuits using reasoning that suggests the remaining 450 cases may also be rejected. The company underwent a CEO transition, with long-time chief executive Petras moving to executive chairman whilst Shader joined from medical device services company Viant. McIntyre believes Sotera Health's former private equity owners completed their exit after Q1 earnings, removing selling pressure that had weighed on shares. The firm estimates the company could earn approximately $1.30 per share in 2028.

Yahoo Finance
Aug 7th, 2026
Sotera Health revenue rises 8% as new CEO takes helm, raises full-year outlook

Sotera Health reported second-quarter 2026 results showing 8% constant-currency revenue growth and improved margins. Revenue rose 9.2% year-over-year to $321 million, whilst adjusted EBITDA increased 10% to $166 million, with margins expanding to 51.6%. The company announced a leadership transition, with Alton Shader becoming chief executive officer on 26 May, succeeding Michael Petras, who remains executive chairman. Sterigenics revenue increased 8.6% to $212 million, driven by favourable pricing and volume improvements. Nordion saw 15.8% revenue growth to $49 million, primarily from Cobalt-60 harvest timing. Nelson Labs revenue rose 6.3% to $61 million. Interest expense declined by over $6 million to $34 million, attributed to term-loan repricing and debt reduction completed in 2025. Sotera Health raised its full-year revenue and adjusted EBITDA outlook.

MarketBeat
Aug 7th, 2026
Sotera Health Q2 earnings call highlights.

Sotera Health Q2 earnings call highlights. August 7, 2026 Key points. * Strong second-quarter performance: Sotera Health reported 9.2% revenue growth to $321 million, 10% adjusted EBITDA growth to $166 million and a 36-basis-point margin expansion. Adjusted EPS rose 30% to $0.26, supported partly by lower interest expense. * 2026 outlook raised: The company increased its revenue forecast to $1.236 billion-$1.254 billion, adjusted EBITDA guidance to $634 million-$643 million and adjusted EPS guidance to $0.95-$1.01 after strong first-half results. * Investment and strategic updates: Capital expenditures are expected to reach $200 million-$225 million in 2026 as Sotera expands capacity and upgrades facilities, while net leverage declined to three times. The company is also reviewing potential M&A opportunities and navigating leadership changes and ongoing litigation. * Five stocks to consider instead of Sotera Health. Sotera Health NASDAQ: SHC reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook. The company also marked a leadership transition during the quarter. Alton Shader became chief executive officer on May 26, succeeding Michael Petras, who remains executive chairman. Petras said the company had experienced a "seamless transition," while Shader said his initial priorities include understanding the business, assessing talent, strengthening customer partnerships and building on the company's customer-focused culture. Second-Quarter results. Revenue rose 9.2% from the prior-year period to $321 million, or 8% on a constant-currency basis. GAAP net income was $54 million, or $0.19 per diluted share. Adjusted EBITDA increased 10% to $166 million, representing 8.7% constant-currency growth, while adjusted EBITDA margin expanded 36 basis points to 51.6%. Adjusted earnings per share increased 30% year over year to $0.26. Interest expense totaled $34 million, down more than $6 million from the prior-year quarter. Chief Financial Officer Jon Lyons attributed the decline primarily to term-loan repricing and debt-reduction actions completed in 2025, along with lower interest rates. Including its most recent repricing, the company said it has reduced the borrowing cost on its $1.4 billion term loan by 100 basis points in less than a year. * Sterigenics: Revenue increased 8.6% to $212 million, or 7% on a constant-currency basis. Growth reflected 4.3% favorable pricing, 2.7% improvement in volume and mix, and foreign-currency benefits. Segment income rose 9.6% to $118 million, while margin improved 53 basis points. * Nordion: Revenue increased 15.8% to $49 million, or 16.7% on a constant-currency basis. Higher volume and mix, tied to the timing of Cobalt-60 harvest schedules, contributed 13.6% to growth, while pricing added 3.1%. Segment income rose 19.2% to $28 million and margin expanded 160 basis points to 56.9%. * Nelson Labs: Revenue rose 6.3% to $61 million, or 5.4% on a constant-currency basis, supported by pricing and volume and mix. Segment income was $20 million, up 0.6% as reported but down 0.6% on a constant-currency basis. Segment margin improved 438 basis points sequentially but declined from the prior-year quarter because of higher costs. Shader said Nelson Labs benefited from customer work that exceeded expectations during the quarter, including time-sensitive and critical projects. He said some of the additional business was completed in the quarter, while other customer work is expected to continue through the year. Outlook raised after first-half performance. Based on its first-half results and expectations for the remainder of the year, Sotera Health raised its 2026 outlook. The company now expects revenue of $1.236 billion to $1.254 billion, representing constant-currency growth of 5.25% to 6.75%. It forecasts adjusted EBITDA of $634 million to $643 million, representing constant-currency growth of 5.75% to 7.25%. Discover more MarketBeat All Access EV Market Report The forecast assumes total-company pricing within the company's long-term 3% to 4% range. Sotera Health expects Sterigenics to post mid- to high-single-digit constant-currency revenue growth for the year, Nordion to grow in the low- to mid-single digits, and Nelson Labs to deliver low-single-digit growth. Nelson Labs' segment income margin is expected to remain in the low- to mid-30% range. Lyons said Nordion's first-half revenue came in above the company's earlier expectation that the period would account for roughly 40% to 45% of full-year segment revenue. Certain shipments originally anticipated for the second half occurred in the second quarter at customer request. The company expects Nordion's second-half revenue to be approximately evenly split between the third and fourth quarters. Management also increased its adjusted EPS outlook to $0.95 to $1.01 from a prior range of $0.93 to $1.01. It reduced its interest-expense outlook to $135 million to $142 million and improved its effective tax-rate outlook on adjusted net income to 27% to 28%. Capacity investments, cash flow and capital allocation. Operating cash flow was approximately $88 million during the quarter. Capital expenditures totaled $46 million, including investments in Sterigenics capacity expansion, ethylene oxide facility upgrades, Nordion Cobalt-60 development initiatives and a Nelson Labs clean-room expansion. The company now expects 2026 capital expenditures of $200 million to $225 million. Management said spending is being driven by growth projects and facility enhancements, with the EO-related enhancements expected to be substantially complete by the end of 2026, though some work and spending will extend into 2027. Lyons said the company still expects a meaningful decline in capital expenditures in 2027 and remains on track with its previously stated three-year free-cash-flow commitment of $500 million to $600 million. Sotera Health's net leverage ratio declined to three times during the second quarter, reaching its long-term target range of two to three times. Shader said management is reviewing capital-allocation priorities as part of its strategic planning process, while noting continued focus on internal investments and potential M&A opportunities in sterilization and Nelson Labs. Leadership and litigation updates. Nelson Labs President Joe Shrawder retired after six years with the company. Riaz Bandali, formerly president of Nordion, has assumed leadership of Nelson Labs. Sotera Health said it is progressing in its search for Bandali's successor at Nordion. On litigation, Petras said a New Mexico matter was settled in July for an amount that was not material to the company and that the settlement fully resolved the claims in that lawsuit. In Georgia, the company is proceeding through the appellate process and expects an update in the spring or summer. Petras said California trials are currently expected in January or April 2027, though timing could change based on court proceedings. About Sotera Health (NASDAQ:SHC). Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market. Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Sotera Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sotera Health wasn't on the list. While Sotera Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Yahoo Finance
Aug 6th, 2026
Sotera Health raises 2026 guidance on 8% revenue growth and pricing gains

Sotera Health reported 8% constant currency revenue growth in Q2 2026, driven by strong performance across its Sterigenics and Nordion segments. Sterigenics benefited from stable demand and 4.3% favourable pricing, whilst Nelson Labs exceeded expectations with 5.4% growth. The company raised its full-year 2026 guidance, now projecting constant currency revenue growth of 5.25–6.75% and adjusted EBITDA growth of 5.75–7.25%. Capital expenditures are forecast at $200 million to $225 million for 2026, with a significant reduction expected in 2027 as facility upgrades near completion. Sotera Health reached its target leverage range of 2x to 3x, providing increased flexibility for capital allocation. The company completed a leadership transition at Nelson Labs and settled EO-related litigation in New Mexico for an immaterial amount.